Recon: MHRA approves Novo’s weight-loss pill; Some US employers look to cut GLP-1 coverage in 2027
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
In Focus: US
- OB-GYN association, deviating from CDC guidance, issues its own vaccine recommendations (STAT)
- Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases (Reuters)
- U.S. drug regulator issues import alert for drugs made at a Dabur India plant (Reuters)
- CDC Activates Screwworm Emergency Response as Cases Increase (Bloomberg)
- Screwworm Treatment for Pets Receives Emergency FDA Approval (Bloomberg)
In Focus: International
- As the U.S. looks on, European countries feel growing pressure on drug prices (STAT)
- Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says (Reuters)
- Novo Nordisk flags patient data breach from some clinical trials in cyberattack (Reuters)
- Weight-Loss Drugs Cut UK Food Bills by £780 Million, Study Shows (Bloomberg)
- Novo’s Wegovy Pill Wins Approval in UK for Obesity Treatment (Bloomberg) (Reuters)
- Heart Health Biotech Kardigan Seeks $373.3 Million in US IPO (Bloomberg)
- China Lures Foreign Patients With Cutting-Edge, Cheap Medical Care (Bloomberg)
Pharma & Biotech
- Enliven Therapeutics’ leukemia drug shows promise in new study (STAT)
- ‘Synthetic lethality’ could trigger another round of biotech M&A (STAT)
- Cancer Drugmaker Parabilis Surges 58% in US Trading Debut (Bloomberg)
- Here are biopharma’s 10 highest-paid scientists and doctors for 2025 (Endpoints)
- Summit withdraws $500M offering, citing 'market conditions' (Endpoints)
- Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says (Endpoints)
- Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO (Endpoints)
- Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3 (Endpoints)
- Neion Bio lands $23M Series A to make proteins from chicken eggs (Endpoints)
- Exclusive: Genentech lays off top scientist Vishva Dixit, closes infectious disease research unit in restructuring (Endpoints)
- Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (Reuters)
Medtech
- Danaher closes $9.9B Masimo buyout (MedTech Dive)
- Why Insulet thinks its fully closed loop system will stand apart from rivals (MedTech Dive)
- Vague AI Literacy Requirements For Medtech Signal A Problem In Europe (MedTech Insight)
- Endogene.bio CEO On A Menstrual-Blood Test For Endometriosis (MedTech Insight)
Food & Nutrition
- Campbell’s CEO: ‘Tough decisions’ loom for struggling snack business (Food Dive)
- How grocers are catering to GLP-1 users (Food Dive)
Government, Regulatory & Legal
- Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find (STAT)
- Are Republicans turning against medications for treating opioid addiction? (STAT)
- Scientists see promise in NIH proposal to cap number of grants they receive (STAT)
- We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850 (STAT)
- How long Covid’s scientific stalemate made it politically erasable (STAT)
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.